Globe Newswire
Globe Newswire
More Globe Newswire
View Older Stories View Newer Stories-
ASML reports transactions under its current share buyback program
-
Kayne Anderson Energy Infrastructure Fund Announces Distribution of $0.08 Per Share for June 2025
-
Trump Executive Order Fuels Regulatory Shift—Bitcoin Solaris Positioned to Lead Utility-Driven Crypto Era
-
Solar Alliance Energy, Inc. Announces Q1 Earnings, Continued Progress
-
Teck Provides Update on Chile Operations Maintenance
-
Context Therapeutics Announces CTIM-76 Trial in Progress Poster Presentation at 2025 ASCO Meeting
-
Western Financial Group and the Calgary Stampeders Create Multi-Year Strategic Partnership
-
Papa Johns Canada Introduces Cheddar Crust Pizza, A New Take on a Classic Favourite
-
Repeat: EAT & BEYOND ANNOUNCES PROPOSED NAME CHANGE AND UPDATED INVESTMENT POLICY
-
IN8bio Presents Positive Phase 1 Data of INB-200 in Newly Diagnosed GBM Demonstrating Prolonged Progression-Free Survival
-
New Wave Appoints New Chief Executive Officer
-
Miata Metals Signs Option to Increase Ownership of the Nassau Gold Project in Suriname to 100%
-
CANADA CARBON INC. ANNOUNCES EXTENSION OF PRIVATE PLACEMENT
-
Stifel Completes Acquisition of Bryan Garnier
-
SunStrong Closes $254 Million Securitization of Residential Solar & Battery Systems
-
SunStrong Closes $254 Million Securitization of Residential Solar & Battery Systems
-
Digi Power X Maintains Strong Cash and Crypto Position With No Long-Term Debt and Reports May 2025 Production Results
-
Zefiro Publishes Whitepaper for its Lifecycle Solution Suite of Environmental Technologies
-
Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
BriaCell Reports Robust Overall Survival and Clinical Benefit Data at ASCO 2025
-
Dr Manfred Knof joins DeFi Technologies as Chairman of Valour and Strategic Advisor
-
Prelude Therapeutics to Participate in Upcoming Healthcare Conferences
-
Southern Realty Trust Expands Revolving Credit Facility to $100 Million with Addition of EverBank as Joint Lead Arranger
-
Amerigo Announces Board Appointment
-
BridgeBio to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference 2025
-
Nexxen Announces May 2025 Share Repurchase Program Summary
-
Emerita Provides Comments on Announcement Approving Development of Aznalcollar Project, Spain
-
Sanborn Achieves SOC 2 Type 2 Attestation, Reinforcing Commitment to Data Security and Operational Integrity
-
AVRICORE HEALTH CORPORATE UPDATE: Q1 Results and Ongoing Progress Report
-
Form 8.3 - [GLOBALDATA PLC - 30 05 2025] - (CGWL)
-
Form 8.3 - Alphawave IP Group plc
-
Form 8.3 - [CRANEWARE PLC - 30 05 2025] - (CGWL)
-
dsm-firmenich completes sale of its stake in Feed Enzymes Alliance to Novonesis for €1.5 billion
-
Signify share repurchase period update
-
Novonesis completes acquisition of dsm-firmenichs’s share of the Feed Enzyme Alliance
-
Regeneron Expands Clinical-Stage Obesity Portfolio with Strategic In-Licensing of Novel Dual GLP-1/GIP Receptor Agonist
-
uniQure Provides Regulatory Update on AMT-130 for Huntington’s Disease
-
Dynacor Group Declares June 2025 Dividend
-
USW welcomes federal commitment to Canadian steel and aluminum in national infrastructure and defence projects
-
Asante Receives Second US$100 Million Advance From Fujairah, Provides Interim Financing Update
-
BioCryst to Present New Data at 2025 Meeting of the European Academy of Allergy and Clinical Immunology
-
Relay Therapeutics Announces Updated Data for RLY-2608 + Fulvestrant Further Demonstrating Clinically Meaningful Progression Free Survival at ASCO 2025
-
Sanofi Exercises License Extension Option to Nurix’s STAT6 Program
-
Immunocore to present at the 2025 Jefferies Global Healthcare Conference
-
Nokia and Andorix partner to accelerate Private 5G and Edge solutions in North American real estate market
-
Marex Group plc to Participate in Upcoming Piper Sandler Global Exchange & Trading Conference
-
Highwoods Provides Leasing Update
-
Rocky Shore Announces the Sale of its Hemlo-Area Claims
-
Helium Evolution Closes Second Tranche of Expanded Private Placement
-
Reviva Announces Positive Full Dataset for 1-Year Phase 3 RECOVER Open Label Extension Study Evaluating Brilaroxazine in Schizophrenia
